Nancy E Thomas1, Klaus J Busam, Lynn From, Anne Kricker, Bruce K Armstrong, Hoda Anton-Culver, Stephen B Gruber, Richard P Gallagher, Roberto Zanetti, Stefano Rosso, Terence Dwyer, Alison Venn, Peter A Kanetsky, Pamela A Groben, Honglin Hao, Irene Orlow, Anne S Reiner, Li Luo, Susan Paine, David W Ollila, Homer Wilcox, Colin B Begg, Marianne Berwick. 1. Nancy E. Thomas, Pamela A. Groben, Honglin Hao, and David W. Ollila, University of North Carolina, Chapel Hill, NC; Klaus J. Busam, Irene Orlow, Anne S. Reiner, and Colin B. Begg, Memorial Sloan-Kettering Cancer Center, New York, NY; Lynn From, Women's College Hospital, Toronto, Ontario; Richard P. Gallagher, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada; Anne Kricker and Bruce K. Armstrong, The University of Sydney, Sydney, New South Wales; Alison Venn, Menzies Research Institute, Tasmania, Australia; Hoda Anton-Culver, University of California, Irvine; Stephen B. Gruber, University of Southern California, Los Angeles, CA; Roberto Zanetti and Stefano Rosso, Center for Cancer Prevention, Torino, Italy; Terence Dwyer, International Agency for Research on Cancer, Lyon, France; Peter A. Kanetsky, University of Pennsylvania, Philadelphia, PA; Li Luo, Susan Paine, and Marianne Berwick, University of New Mexico, Albuquerque, NM; and Homer Wilcox, New Jersey Department of Health, Trenton, NJ.
Abstract
PURPOSE: Although most hospital-based studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary melanomas, it is uncertain whether TILs provide prognostic information beyond existing melanoma staging definitions. We addressed the issue in an international population-based study of patients with single and multiple primary melanomas. PATIENTS AND METHODS: On the basis of the Genes, Environment and Melanoma (GEM) study, we conducted follow-up of 2,845 patients diagnosed from 1998 to 2003 with 3,330 invasive primary melanomas centrally reviewed for TIL grade (absent, nonbrisk, or brisk). The odds of TIL grades associated with clinicopathologic features and survival by TIL grade were examined. RESULTS: Independent predictors (P < .05) for nonbrisk TIL grade were site, histologic subtype, and Breslow thickness, and for brisk TIL grade, they were age, site, Breslow thickness, and radial growth phase. Nonbrisk and brisk TIL grades were each associated with lower American Joint Committee on Cancer (AJCC) tumor stage compared with TIL absence (P(trend) < .001). Death as a result of melanoma was 30% less with nonbrisk TIL grade (hazard ratio [HR], 0.7; 95% CI, 0.5 to 1.0) and 50% less with brisk TIL grade (HR, 0.5; 95% CI, 0.3 to 0.9) relative to TIL absence, adjusted for age, sex, site, and AJCC tumor stage. CONCLUSION: At the population level, higher TIL grade of primary melanoma is associated with a lower risk of death as a result of melanoma independently of tumor characteristics currently used for AJCC tumor stage. We conclude that TIL grade deserves further prospective investigation to determine whether it should be included in future AJCC staging revisions.
PURPOSE: Although most hospital-based studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary melanomas, it is uncertain whether TILs provide prognostic information beyond existing melanoma staging definitions. We addressed the issue in an international population-based study of patients with single and multiple primary melanomas. PATIENTS AND METHODS: On the basis of the Genes, Environment and Melanoma (GEM) study, we conducted follow-up of 2,845 patients diagnosed from 1998 to 2003 with 3,330 invasive primary melanomas centrally reviewed for TIL grade (absent, nonbrisk, or brisk). The odds of TIL grades associated with clinicopathologic features and survival by TIL grade were examined. RESULTS: Independent predictors (P < .05) for nonbrisk TIL grade were site, histologic subtype, and Breslow thickness, and for brisk TIL grade, they were age, site, Breslow thickness, and radial growth phase. Nonbrisk and brisk TIL grades were each associated with lower American Joint Committee on Cancer (AJCC) tumor stage compared with TIL absence (P(trend) < .001). Death as a result of melanoma was 30% less with nonbrisk TIL grade (hazard ratio [HR], 0.7; 95% CI, 0.5 to 1.0) and 50% less with brisk TIL grade (HR, 0.5; 95% CI, 0.3 to 0.9) relative to TIL absence, adjusted for age, sex, site, and AJCC tumor stage. CONCLUSION: At the population level, higher TIL grade of primary melanoma is associated with a lower risk of death as a result of melanoma independently of tumor characteristics currently used for AJCC tumor stage. We conclude that TIL grade deserves further prospective investigation to determine whether it should be included in future AJCC staging revisions.
Authors: Esther Edlundh-Rose; Suzanne Egyházi; Katarina Omholt; Eva Månsson-Brahme; Anton Platz; Johan Hansson; Joakim Lundeberg Journal: Melanoma Res Date: 2006-12 Impact factor: 3.599
Authors: Farhad Azimi; Richard A Scolyer; Pavlina Rumcheva; Marc Moncrieff; Rajmohan Murali; Stanley W McCarthy; Robyn P Saw; John F Thompson Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: D E Elder; D Guerry; M VanHorn; S Hurwitz; L Zehngebot; L I Goldman; D LaRossa; R Hamilton; E E Bondi; W H Clark Journal: Cancer Date: 1985-07-15 Impact factor: 6.860
Authors: M Mandalà; G L Imberti; D Piazzalunga; M Belfiglio; R Labianca; M Barberis; L Marchesi; P Poletti; L Bonomi; L Novellino; K Di Biagio; A Milesi; U Guerra; C Tondini Journal: Eur J Cancer Date: 2009-06-22 Impact factor: 9.162
Authors: Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox Journal: Adv Anat Pathol Date: 2017-11 Impact factor: 3.875
Authors: Nicholas J Taylor; Nancy E Thomas; Hoda Anton-Culver; Bruce K Armstrong; Colin B Begg; Klaus J Busam; Anne E Cust; Terence Dwyer; Lynn From; Richard P Gallagher; Stephen B Gruber; Diane E Nishri; Irene Orlow; Stefano Rosso; Alison J Venn; Roberto Zanetti; Marianne Berwick; Peter A Kanetsky Journal: Int J Cancer Date: 2016-05-30 Impact factor: 7.396
Authors: Nancy E Thomas; Sharon N Edmiston; Irene Orlow; Peter A Kanetsky; Li Luo; David C Gibbs; Eloise A Parrish; Honglin Hao; Klaus J Busam; Bruce K Armstrong; Anne Kricker; Anne E Cust; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway Journal: J Invest Dermatol Date: 2018-05-09 Impact factor: 8.551